4th February, 2014, Strasbourg, France A unique group of patient advocacy organisations, healthcare leaders (including two former health ministers and a Nobel Laureate) and Members of the European Parliament against Cancer (MAC) have come together to launch the European Cancer Patient’s Bill of Rights to coincide with World Cancer Day, in the European Parliament in Strasbourg.
An EORTC study published in the Lancet Oncology found that health-related quality of life (HRQOL) assessment in small-cell lung cancer randomized clinical trials provides relevant added information in studies where the treatment arms do not differ in terms of efficacy. More importantly, it provides valuable information for those treatments where better HRQOL is associated with overall survival benefit.
Paris, 22 January 2014 - The WIN Consortium proudly announced that Scott P. Serota, President and CEO of the Blue Cross and Blue Shield Association (BCBSA), will deliver the opening address of the WIN 2014 Symposium.
Appearing in Lancet Oncology, long term results of EORTC trial 22921 with 10.4 years median follow-up show that 5-FU (fluorouracil) based adjuvant chemotherapy after preoperative (chemo)-radiotherapy for patients with cT3-resectable T4 M0 rectal cancer does not improve survival or disease-free survival.
Cancer biology and optimal radiotherapy delivery are intricately related, and [...]
Her Royal Highness Princess Astrid cedes Honorary Presidency of the EORTC Charitable Trust to His Serene Highness Prince Albert of Monaco.
This event took place in the presence of Princess Astrid, Prince Lorenz and Prince Albert at EORTC Headquarters in Brussels.
Read more:
The WIN (Worldwide Innovative Networking in personalized cancer medicine) Consortium General Assembly unanimously voted adhesion of the EORTC to the WIN Consortium.
WIN Consortium is a non-profit global collaboration of leading academic, industry, healthplan and advocacy organizations. It focusses its efforts on running global research projects to identify biomarkers for targeted therapies as well as clinical trials to investigate targeted cancer treatments.
First line treatment for patients with metastatic prostate cancer generally consists of androgen deprivation therapy. This can be achieved by administering gonadotropin releasing hormone analogs, or even by surgical castration. Even though the majority of patients initially respond to this treatment, for most patients the tumor eventually progresses despite castration levels of testosterone and reaches a stage known as “castration resistant” disease. The median duration of disease control is only 13 to 22 months, and overall survival is 28 to 36 months.
Results of the EORTC and GIMEMA (Gruppo Italiano Malattie Ematologiche dell’ Adulto) AML-12 Trial appearing in the Journal of Clinical Oncology show that high-dose cytarabine in induction treatment improves outcome of adult patients with acute myeloid leukemia (AML). In particular, high-dose cytarabine produces higher remission and survival rates than the standard-dose cytarabine in patients younger than age 46 years old.
Men with Hodgkin lymphoma who want to become fathers after their cancer treatment have greatly increased chances of doing so if they have frozen and stored semen samples beforehand, according to research published online today (Wednesday) in Europe’s leading reproductive medicine journal Human Reproduction.
